Arvinas
ARVNArvinas is a clinical-stage biotechnology company pioneering a new class of therapeutics based on its proprietary PROteolysis TArgeting Chimera (PROTAC) platform.
Earnings
Next report
Aug 5, 2026 (In 3 weeks)Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
By net margin
Profile
Arvinas is a clinical-stage biotechnology company pioneering a new class of therapeutics based on its proprietary PROteolysis TArgeting Chimera (PROTAC) platform. The company leverages the body's natural protein disposal system to selectively degrade and remove disease-causing proteins, specifically targeting those historically considered undruggable. Its primary value proposition lies in developing a novel therapeutic modality for oncology and neurology indications with significant unmet medical needs.
A pioneer in the targeted protein degradation space with the first PROTAC-based New Drug Application accepted by the FDA.
Questions, answered.
- What is Arvinas's market cap?
- Arvinas (ARVN) has a market capitalization of $551.0M and trades on NASDAQ.
- What is Arvinas's revenue and profitability?
- Arvinas generated $89.4M in trailing twelve-month revenue with a net loss of $221.3M, representing a net margin of -247.5%, with free cash flow of -$256.9M. These figures are based on the Q1 2026 filing.
- Who are Arvinas's competitors?
- Arvinas's key competitors include Kymera Therapeutics, C4 Therapeutics, Nurix Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does Arvinas partner with?
- Arvinas's notable partners include Pfizer, Inc., Genentech, Inc., F. Hoffman-La Roche Ltd..
- Where is Arvinas headquartered?
- Arvinas is headquartered in United States of America and employs approximately 445 people. It has been publicly traded since 2018.
